Document is current
Any future updates will be listed below
-
Authors
Wissel, David
Mehlferber, Madison M.
Nguyen, Khue M.
Pavelko, Vasilii
Tseng, Elizabeth
Robinson, Mark D.
Sheynkman, Gloria M.
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (204869)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (204869)
Wagner Fellowship (MMM)
Robert M. Berne Cardiovascular Research Center Training Program (T32HL007284)
Robert M. Berne Cardiovascular Research Center Training Program (T32HL007284)
National Institute of General Medical Sciences (R35GM142647)
National Institute of General Medical Sciences (R35GM142647)
- License Information
-
More Information
Article History
Received: 8 July 2025
Accepted: 29 January 2026
First Online: 25 February 2026
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and was reviewed by the University of Virginia Institutional Review Board for Health Sciences Research (IRB-HSR) and received an exempt determination (Study #301733).
: Not applicable.
: E.T. is employed by and holds stock in Pacific Biosciences of California, Inc. G.M.S. is Chief Scientific Officer and holds equity in NeoSplice Therapeutics, Inc., and serves on the scientific advisory board of Quantum-Si Incorporated and holds stock in Quantum-Si Incorporated. Pacific Biosciences of California, Inc. ran sequencing of PB Kinnex lrRNA-seq on the Revio free of charge.
